News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Astellas Release: Exploratory Analysis Of The Phase I/II CHRYSALIS Study Of Gilteritinib Demonstrates First Molecular Response To FLT3 Inhibitor In Acute Myeloid Leukemia
June 6, 2017
|
3 min read
Twitter
LinkedIn
Facebook
Email
Print
• Maryland Jobs
• Washington Jobs
View More Jobs
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 1
Phase 2
Astellas Pharma US, Inc.
MORE ON THIS TOPIC
Drug Development
Biogen’s Alzheimer’s results bolster tau theory—and Denali’s next gen candidate
May 15, 2026
·
3 min read
·
Annalee Armstrong
Insights
GPCRs, radiopharma and the rise of functional peptide screening
May 14, 2026
·
3 min read
·
Jennifer C. Smith-Parker
Gene therapy
REGENXBIO slumps after serious side effects mar Duchenne gene therapy results
May 14, 2026
·
3 min read
·
Annalee Armstrong
Alzheimer’s disease
Biogen takes tau Alzheimer’s therapy to Phase 3 despite mid-stage fail, prompting cautious optimism
May 14, 2026
·
3 min read
·
Tristan Manalac
